Jump to content

Atorolimumab

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 19:49, 26 November 2022 (Add: s2cid. | Use this bot. Report bugs. | Suggested by BorgQueen | Category:Chemicals that do not have a ChemSpider ID assigned | #UCB_Category 51/851). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Atorolimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetRhD
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Atorolimumab is an immunosuppressive drug directed against the Rhesus factor.[1][2]

References

[edit]
  1. ^ WHO Drug Information
  2. ^ Pelletier JP, Mukhtar F (2020). "Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies". In Maitta RW (ed.). Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. p. 267. doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. S2CID 213508934.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Atorolimumab&oldid=1123985535"